M. Hassan Alkazemi MD MS

Urologic Oncology Fellow @UrologyMSK | via @WashU_Uro @DukeMedSchool & @Yale |

[UrologyMSK @UrologyMSK]

Congrats to all the @UroOnc matches today! A special shout out to our crew!

[Bernie Bochner, MD @bbmdmsk]

Congratulations to each of these amazing people. The future of urologic oncology is in great hands Will done guys👏🏻👏🏻
@gold_uro @YashKhandwalaMD @NickPickersgill @AlkazemiMD @AoZhangUro @vhjayalath

[ari hakimi @arihakimi]

Why do VEGFR-TKI + IO combinations produce impressive responses in ccRCC but often fail to achieve the long-term durability seen with dual checkpoint blockade? Check out our lab's latest in @Cancer_Cell led by the incredible Lyn Vuong!
https://t.co/ASvkCpDzQW

[David H Aggen, MD PhD @Dr_Aggen]

🚀 Exciting advances in NMIBC at @MSKCancerCenter led by @UrologyMSK

🚨 Pragmatic trial for BCG-refractory NMIBC
Led by Eugene Pietzak (@eugene_pietzak) — Trial #25-069 / NCT06929286
https://t.co/F5DuW99AQu
https://t.co/GZAW6CeR8u

🚨 CD40 Agonist Trial for BCG-unresponsive NMIBC
Led by Bernie Bochner (@bbmdmsk) A shining example of bench to bedside medicine co-led by @juanosoriomd Trial #21-314 / NCT05126472.
https://t.co/2oWyfk5iwf
https://t.co/U4MeRXS0SL

Proud work from @urologymsk @MSKCancerCenter @BladderCancerUS

[David H Aggen, MD PhD @Dr_Aggen]

🚨 New trial options at @MSKCC for advanced bladder cancer after EV+P.

• HER2-targeted ADC: https://t.co/SERUMoBXZr (Disitamab Vedotin)
• TROP2-ADC: https://t.co/sApX2LHNVv (Datopotomab Deruxtecan)
• Nectin-4-ADC: https://t.co/QmYfgPk5eM (“Nectin-4 targeted ADCs”)
• Pan-tumor CDH6-ADC: https://t.co/H91uRg104O (Raludotatug Deruxtecan)

@MSK_Urology @MSK_DeptOfMed @MSKCC #BladderCancer #ClinicalTrials

[Max Kates @MaxKates]

“I know there’s a lot of people out there going through what I am going through and dealing with what I am dealing with and let’s stop being ashamed of it and let’s deal with it. And let’s deal with it head on.”
👊❤️I'm a @DeionSanders fan now and always @BladderCancerUS

[UrologyMSK @UrologyMSK]

🥇🥇🥇We are thrilled to announce our number one ranking in Urology for the third straight year! Truly a testament to our amazing team of techs, nurses, APPs
and fellows!@MSKCancerCenter
https://t.co/hjTtUoDaKJ

[UrologyMSK @UrologyMSK]

Congratulations to @arihakimi who was chosen unanimously by the class of 2025 Urologic Oncology Fellows as Teacher of the Year. Well deserved! @MTDawidek @MariaPereMD @sunny_nal @therealUroJET @UroMuneeb

[Eric Klein @EricKleinMD]

What does it mean to be a surgical oncologist? I never fully understood till I retired... https://t.co/I9to0MzPfO

[Karim Touijer @TouijerKarim]

Great distinction from @EUplatinum for our trial on pelvic lymph node dissection in #prostatecancer .
Gratitude to the patients who participated in the trial and my @UrologyMSK colleagues. Moving forward together towards finding answers to important questions in cancer care.

[Wesley Yip @WesleyYipMD]

Very excited to see our #bladdercancer and #UTUC review now published in @CACancerJournal, written with the collaborative effort of many friends of @BladderCancerUS and patient advocate Mary Sullivan. ADCs, TMT, HR-NMIBC, geriatric care, female RC, kidney-sparing, and more!

[M. Hassan Alkazemi MD MS @AlkazemiMD]

Humbled and honored to be among this year’s @ConquerCancerFd YIA grant recipients. Indebted to my mentors — Dr. @eugene_pietzak , Dr. @IyerGopa , and the team at @UrologyMSK @MSKCancerCenter — for their unwavering guidance and support. Excited for the future #ASCO25

[Conquer Cancer, the ASCO Foundation @ConquerCancerFd]

Congratulations to this year’s class of Conquer Cancer grant and award recipients! Are you one of them? Tell us in the comments! We can't wait to celebrate with you at #ASCO25. Full list of recipients: https://t.co/aE89Mrvgeu
@ASCO

[UrologyMSK @UrologyMSK]

Our rockstar fellows are continuously making us so proud! A special shout out to @YashKhandwalaMD and @AlkazemiMD for their @ConquerCancerFd awards at #ASCO25

[BackTable Urology @_backtableUro]

Dr. Clinton and Dr. Pietzak discussed the management of BCG-refractory NMIBC and highlighted recent BCG and gemcitabine clinical trials as well as new non-BCG therapies

#BladderCancerAwarenessMonth #URO64

https://t.co/RPk8ABFgaT

[Bernie Bochner, MD @bbmdmsk]

Terrific day #1 of our open surgical skills training program for our @UrologyMSK research fellows about to start their clinical year of training. Tremendous partners @HartfordHealthC @MSKCancerCenter

[UrologyMSK @UrologyMSK]

Amazing Whitmore Visiting Professor visit from ⭐️ alum @uroegg! Spent time with our fellows and faculty and gave an outstanding lecture to surgical grand rounds on mythology and dogma in surgery!

[M. Hassan Alkazemi MD MS @AlkazemiMD]

Had a great time learning the continuous re-evaluation/staccato/“tap-tap” technique for complex TURBTs with @bbmdmsk @DrJohnSfakianos @JoshMeeks at the Olympus-sponsored course @Olympus_Corp this past weekend. Highly recommend urologists apply in the future—participants ranged from PGY-2s to fellows and even seasoned attendings! #Urology #SurgicalEducation Also stopped by Mike’s pastry on the way there 😋

[Bernie Bochner, MD @bbmdmsk]

Book another successful hands-on TURBT course. Life like models, incredible support by @Olympus_Corp

Thank you to my colleagues @DrJohnSfakianos @JoshMeeks for sharing your expertise

Thank you to the 2025 attendings, fellows and residents that participated. 💪👏👏

[M. Hassan Alkazemi MD MS @AlkazemiMD]

Excited to share our latest work on micropapillary bladder cancer presented at #ASCOGU25! We conducted a retrospective survival analysis to better understand outcomes in this rare variant - focusing on percentage of MP disease in the cystectomy sample. Watch the full discussion with @h_alahmadie @UroDocAsh @urotoday @MSKCancerCenter @UrologyMSK

[Bladder Cancer Advocacy Network @BladderCancerUS]

Video in @Urotoday: Micropapillary Histology in Bladder Cancer: A Retrospective Survival Analysis - with @Urodocash @alkazemimd & @h_alahmadie. Click here to watch the video: https://t.co/z7QlUELhgY

[Bernie Bochner, MD @bbmdmsk]

Another useful strategy for pts with NMIBC previously exposed to BCG

Great work by @eugene_pietzak and the @UrologyMSK team
@MSKCancerCenter